Variant LTC4 synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukast

Thorax

Volumn 55, Issue SUPPL. 2, 2000, Pages

  Sampson, A P ^a   Siddiqui, S ^a   Buchanan, D ^a   Howarth, P H ^a   Holgate, S T ^a   Holloway, J W ^a   Sayers, I ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONATE 5 LIPOXYGENASE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LEUKOTRIENE C4 SYNTHASE; PEPTIDOLEUKOTRIENE; ZAFIRLUKAST;

ADULT; AGED; ASTHMA; BRONCHOSPASM; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG SENSITIVITY; EOSINOPHIL; FATTY ACID SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; MALE; MEDIATOR RELEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

ADULT; AGED; ALLELES; ANTI-ASTHMATIC AGENTS; ASTHMA; CYSTEINE; EOSINOPHILS; FEMALE; GENOTYPE; GLUTATHIONE TRANSFERASE; HUMANS; LEUKOTRIENE ANTAGONISTS; LEUKOTRIENES; MALE; MIDDLE AGED; PROGNOSIS; RESPIRATORY MECHANICS; TOSYL COMPOUNDS;

EID: 0033803781     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (17)

1. 1 Sampson AP, Holgate ST. Leukotriene modifiers in the treatment of asthma: look promising across the board of asthma severity. BMJ 1998;316:1257-8.
2. 4 and methacholine on sputum cell differentials in asthma. Am J Respir Crit Care Med 1997;155:1247-53.
3. 4 and granulocytic infiltration into asthmatic airways. Lancet 1993;341:989-90.
4. 4 Leff AR, Busse WW, Pearlman D, et al. Montelukast, a leukotriene receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med 1998;339:147-52.
5. 4 synthase in bronchial biopsies of aspirin-intolerant asthmatics. J Clin Invest 1998;101:834-46.
6. 6 Seymour ML, Aberg D, Riise G, et al. Seasonal allergen exposure increases expression of leukotriene pathway enzymes and induces eosinophil influx in bronchial mucosa of atopic asthmatics. J Allergy Clin Immunol 1998;101:711 (abstract).
7. 7 Lynch KR, O'Neill GP, Liu Q, et al. Characterization of the human cysteinyl leukotriene CysLT, receptor. Nature 1999;399:789-93.
8. 8 Sarau HM, Ames RS, Chambers J, et al. Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor. Mol Pharmacol 1999;56: 657-63.
9. 4 synthase during the development of eosinophils in vitro from cord blood progenitors. Blood 1996;88:4338-47.
10. 10 Cowburn AS, Holgate ST, Sampson AP. IL-5 increases expression of 5-lipoxygenase-activating protein and translocates 5-lipoxygenase to the nucleus in human blood eosinophils. J Immunol 1999;163:456-65.
11. 11 Sanak M, Sampson AP. Biosynthesis of cysteinylleucotrienes in aspirin-intolerant asthma. Clin Exp Allergy 1999;29:306-13.
12. 12 In K, Asano K, Beler D, et al. Naturally-ocurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. J Clin Invest 1997;99:1130-7.
13. 13 Silverman ES, Du J, De Sanctis GT, et al. Egr-1 and Sp1 interact functionally with the 5-lipoxygenase promoter and its naturally occurring mutants. Am J Respir Cell Mol Biol 1998;19:316-23.
14. 14 Drazen JM, Yandava CN, Dube L, et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nature Genet 1999;22: 168-70.
15. 15 Szczeklik A, Stevenson DD. Aspirin-induced asthma: advances in pathogenesis and management. J Allergy Clin Immunol 1999;104:5-13.
16. 4 synthase promoter polymorphism and risk of aspirin-induced asthma. Lancet 1997;350:1599-600.
17. 4 synthase (LTC4S) in peripheral blood leukocytes of patients with asthma. Eur J Clin Invest 1998;28: A50.